Lumosa Therapeutics Company Description

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan.

The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery.

It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology.

Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

Lumosa Therapeutics Co., Ltd.

Country	Taiwan
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	39
CEO	Sheng Wen Yeh

Contact Details

Address: No. 3-2, Park Street Taipei Taiwan
Phone	886 2 2655 7918

Stock Details

Ticker Symbol	6535
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006535008
SIC Code	2836

Key Executives

Name	Position
Sheng Wen Yeh	General Manager
Li Fang Pan	Chief Financial Officer and Manager of the Administrative Office
Pei-Jiun Chen	Chief Operating Officer
Lan Ying Huang	Accounting Supervisor